


The premier international
meeting featuring novel cancer therapeutics

Abstract Submission Deadline: Monday, August 12
Early Registration Deadline: Friday, August 9



CALL FOR ABSTRACTS

AACR-NCI-EORTC International Conference

MOLECULAR TARGETS and CANCER THERAPEUTICS

October 19-23, 2013 • Hynes Convention Center, Boston, MA

www.AACR.org

Continuing Medical Education Activity *AMA PRA Category 1 Credits™* available

Organizing and Scientific Committees

Organizing Committee Co-Chairpersons:

Frank McCormick, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA (**AACR**)*

James H. Doroshow, National Cancer Institute-DCTD, Bethesda, MD, USA (**NCI**)*

Roger Stupp, University Hospital (CHUV), Lausanne, Switzerland (**EORTC**)*

Scientific Committee Co-Chairpersons:

Jeffrey A. Engelman, Massachusetts General Hospital, Charlestown, MA, USA (**AACR**)*

Lee J. Helman, National Cancer Institute, Bethesda, MD, USA (**NCI**)*

Sabine Tejpar, Catholic University of Leuven, Leuven, Belgium (**EORTC**)*

Scientific Committee:

Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA (**AACR**)

Ahmad H. Awada, Institut Jules Bordet, Brussels, Belgium (**EORTC**)*

Fatima Cardoso, Champalimaud Cancer Center, Lisbon, Portugal (**EORTC**)

Phillippe Cassier, Centre Léon Bérard, Lyon, France (**EORTC**)

David D. Chang, Amgen, Inc., Thousand Oaks, CA, USA (**AACR**)

Helen X. Chen, National Cancer Institute-CTEP, Rockville, MD, USA (**NCI**)

Elizabeth Cohen-Jonathan, Institut Claudius Regaud, Toulouse, France (**EORTC**)

Jerry M. Collins, National Cancer Institute-DCTD, Bethesda, MD, USA (**NCI**)

Barbara A. Conley, National Cancer Institute-DCTD, Rockville, MD, USA (**NCI**)

Sara A. Courtneidge, Sanford-Burnham Medical Research Institute, La Jolla, CA, USA (**AACR**)

Christian Ditttrich, Ludwig Boltzmann Institute for Applied Cancer Research, Vienna, Austria (**EORTC**)

Glenn Dranoff, Dana-Farber Cancer Institute, Boston, MA, USA (**AACR**)

Dean Fennell, Leicester Royal Infirmary, Leicester, United Kingdom (**EORTC**)

Levi A. Garraway, Dana-Farber Cancer Institute, Boston, MA, USA (**AACR**)

Toby Tucker Hecht, National Cancer Institute, Rockville, MD, USA (**NCI**)

S. Percy Ivy, National Cancer Institute-DCTD, Rockville, MD, USA (**NCI**)

Paula M. Jacobs, National Cancer Institute-DCTD, Bethesda, MD, USA (**NCI**)

Bernd Kasper, University of Heidelberg, Heidelberg, Germany (**EORTC**)

Scott Kopetz, The University of Texas MD Anderson Cancer Center, Houston, TX, USA (**AACR**)

Annette K. Larsen, INSERM U673, Hôpital de Paris, Paris, France (**EORTC**)

Emma M. Lees, Novartis Institutes for BioMedical Research, Emeryville, CA, USA (**AACR**)

Lisa Licitra, Istituto Nazionale dei Tumori, Milan, Italy (**EORTC**)

W. Marston Linehan, National Cancer Institute, Bethesda, MD (**NCI**)

Iwona Lugowska, Maria Skłodowiek-Curie Memorial Cancer Center, Warsaw, Poland (**EORTC**)

Philippe Maingon, Centre Georges-François Leclerc, Dijon, France (**EORTC**)

Elaine Mardis, Washington University School of Medicine, Saint Louis, MO, USA (**AACR**)*

Gordon B. Mills, The University of Texas MD Anderson Cancer Center, Houston, TX, USA (**AACR**)

Ralph E. Parchment, SAIC-Frederick, Inc., Frederick, MD, USA (**NCI**)

Godefridus J. Peters, Vrije Universiteit Medisch Centrum, Amsterdam, The Netherlands (**EORTC**)

Yves G. Pommier, National Cancer Institute-CCR, Bethesda, MD, USA (**NCI**)*

Victoria M. Richon, Sanofi Oncology, Cambridge, MA, USA (**AACR**)

Jeffrey E. Settleman, Genentech, Inc., South San Francisco, CA, USA (**AACR**)*

Emad Shash, EORTC, Brussels, Belgium (**EORTC**)

Alice T. Shaw, Massachusetts General Hospital Cancer Center, Boston, MA, USA (**AACR**)

Kevan Shokat, University of California, San Francisco, CA, USA (**AACR**)

David B. Solit, Memorial Sloan-Kettering Cancer Center, New York, NY, USA (**AACR**)

Jean-Charles Soria, Institut Gustave-Roussy, Villejuif, France (**EORTC**)*

Louis M. Staudt, National Cancer Institute, Bethesda, MD (**NCI**)*

Patricia S. Steeg, National Cancer Institute, Bethesda, MD, USA (**NCI**)

Charles Swanton, Cancer Research UK, London, United Kingdom (**EORTC**)

Beverly A. Teicher, National Cancer Institute, Rockville, MD, USA (**NCI**)

Joseph E. Tomaszewski, National Cancer Institute-DCTD, Bethesda, MD, USA (**NCI**)

Suzanne L. Topalian, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD, USA (**AACR**)

Matthew G. Vander Heiden, MIT Koch Institute for Integrated Cancer Research, Cambridge, MA, USA (**AACR**)

Mickey Williams, National Cancer Institute-DCTD, Frederick, MD, USA (**NCI**)

John J. Wright, National Cancer Institute-DCTD, Bethesda, MD, USA (**NCI**)

Michael B. Yaffe, MIT Koch Institute for Integrated Cancer Research, Cambridge, MA, USA (**AACR**)

James A. Zwiebel, National Cancer Institute-DCTD, Bethesda, MD, USA (**NCI**)

About the CONFERENCE ORGANIZERS



The American Association for Cancer Research (AACR) is a nonprofit scientific society that includes 34,000 laboratory, translational, and clinical cancer researchers whose mission is to prevent and cure cancer through research, education, communication, and collaboration.



The National Cancer Institute (NCI), founded in 1937, is the principal government agency in the United States charged with coordinating the national effort against cancer. It facilitates international cooperation in clinical trials involving U.S. and foreign collaborating institutions.



The European Organization for Research and Treatment of Cancer (EORTC) offers an integrated approach to drug development, drug evaluation programs, and medical practice. It brings together European cancer translational and clinical research experts from all disciplines for international collaboration.

* - denotes member of Executive Committee

Table of Contents

Organizing and Scientific Committees	Inside Front Cover
Scientific Program and Schedule at-a-Glance	2
Abstract Submission Categories and Guidelines	6
Accommodations and Travel	8
General Information	9
Continuing Medical Education	9
Financial Support for Attendance	9
Press	12
Support and Exhibit Opportunities	13
Webcasts	13
Hotel Reservation Form	14
Registration Form	15



ON THE COVER:

1. Aurora Kinase A inhibitors in bladder cancer: Zhou N, et al. *Clin Cancer Res* April 1, 2013 19:1717-1728.
2. Combined treatment with bortezomib and the histone deacetylase inhibitor valproic acid in ALL Leukemia: Bastian L, et al. *Clin Cancer Res* March 15, 2013 19:1445-1457.
3. RING finger proteins are involved in numerous cancer-related processes such as cell cycle, apoptosis, and DNA repair: Xing C, et al. *Mol Cancer Ther* January 2013 12:94-103.
4. Chemoresistance in pancreatic cancer: Hill R, et al. *Mol Cancer Ther* October 2012 11:2127-2137.
5. Inhibiting autophagy during interleukin-2 immunotherapy: Liang X, et al. *Cancer Res* June 1, 2012 72:2791-2801.
6. EMT: Sun Y, et al. *Cancer Res* January 15, 2012 72:527-536.

Scientific Program and Schedule at-a-Glance*

SATURDAY, OCTOBER 19

Registration

10:00 a.m.-8:00 p.m.

EDUCATIONAL SESSION 1:

Cancer Genomics

3:00 p.m.-4:30 p.m.

Session Co-Chairpersons: Matthew L. Meyerson, Dana-Farber Cancer Institute, Boston, MA, USA and P. Andrew Futreal, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Title to be announced

Matthew L. Meyerson

Challenges and opportunities for genomic medicine

P. Andrew Futreal

Title to be announced

Gad Getz, Broad Institute of MIT and Harvard, Cambridge, MA, USA

EDUCATIONAL SESSION 2:

PI3K and MEK Pathway Inhibitors

4:45 p.m.-6:15 p.m.

Session Co-Chairpersons: Lewis C. Cantley, Weill Cornell Medical College of Cornell University, New York, NY, USA and Richard M. Marais, Paterson Institute for Cancer Research, University of Manchester, Manchester, United Kingdom

BRAF and RAS signaling in melanoma: From basic biology to clinical exploitation

Richard M. Marais

Title to be announced

Neal Rosen, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Title to be announced

Joan S. Brugge, Harvard Medical School, Boston, MA, USA

Networking Reception

6:30 p.m.-8:00 p.m.

SUNDAY, OCTOBER 20

Breakfast

7:00 a.m.-8:00 a.m.

Welcome and Opening Remarks

8:00 a.m.-8:05 a.m.

Jeffrey A. Engelman, Massachusetts General Hospital, Charlestown, MA, USA

Lee J. Helman, National Cancer Institute, Bethesda, MD, USA

Sabine Tejpar, Catholic University of Leuven, Leuven, Belgium

Keynote Lectures

8:05 a.m.-10:05 a.m.

Session Chairperson: Jeffrey A. Engelman, Massachusetts General Hospital, Charlestown, MA, USA

Wnt signaling, Lgr5 stem cells, and cancer

Hans Clevers, Hubrecht Institute, Utrecht, The Netherlands

Targeting the PD-1 pathway: Resetting the balance between the immune system and cancer

Suzanne L. Topalian, Johns Hopkins University School of Medicine, Kimmel Cancer Center, Baltimore, MD, USA

Break

10:05 a.m.-10:30 a.m.

PLENARY SESSION 1:

Latest Advances to Overcome Resistance to Targeted Therapies

10:30 a.m.-12:30 p.m.

Session Co-Chairpersons: René Bernards, Netherlands Cancer Institute, Amsterdam, The Netherlands and Alice T. Shaw, Massachusetts General Hospital Cancer Center, Boston, MA, USA

Title to be announced

René Bernards

Mechanisms of resistance to RAF/MEK inhibitors

David B. Solit, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Title to be announced

William Pao, Vanderbilt University, Nashville, TN, USA

Title to be announced

Alice T. Shaw

(*subject to change, visit www.AACR.org/TargetsConference for an updated program schedule)

Scientific Program and Schedule at-a-Glance*

Poster Session A / Exhibit Show

12:30 p.m.-3:00 p.m.

PLENARY SESSION 2:

Targeting the Metabolic Basis of Cancer

3:15 p.m.-5:15 p.m.

Session Co-Chairpersons: Eyal Gottlieb, Beatson Institute for Cancer Research, Bearsden, Glasgow, United Kingdom and Craig B. Thompson, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

The metabolic phase of the cell cycle

Eyal Gottlieb

Targeting the genetic basis of kidney cancer

W. Marston Linehan, National Cancer Institute, Bethesda, MD, USA

Turning metabolic addiction into cancer therapy

Craig B. Thompson

Additional speaker to be announced

Proffered Paper Session 1

5:30 p.m.-6:30 p.m.

Poster Session A / Exhibit Show (Continued)

6:30 p.m.-7:30 p.m.

MONDAY, OCTOBER 21

Breakfast

7:00 a.m.-8:00 a.m.

PLENARY SESSION 3:

Epigenetic Regulators as Therapeutic Targets

8:00 a.m.-10:00 a.m.

Session Co-Chairpersons: Chas Bountra, University of Oxford, Headington, United Kingdom and James E. Bradner, Dana-Farber Cancer Institute, Boston, MA, USA

Speakers to be announced

Break

10:00 a.m.-10:30 a.m.

PLENARY SESSION 4:

Targeting KRAS Mutant Cancers

10:30 a.m.-12:30 p.m.

Session Co-Chairpersons: Julian Downward, Cancer Research UK, London, United Kingdom and Kevan Shokat, University of California, San Francisco, CA, USA

Specific vulnerabilities of RAS mutant cancer cells

Karen Cichowski, Brigham & Women's Hospital, Boston, MA, USA

Title to be announced

Pasi A. Jänne, Dana-Farber Cancer Institute, Boston, MA, USA

Direct targeting of mutant Ras proteins

Kevan Shokat

Synthetic lethal approaches to targeting Ras mutant cancers

Julian Downward

Poster Session B / Exhibit Show

12:30 p.m.-3:00 p.m.

CONCURRENT SESSIONS 1-4

3:15 p.m.-5:15 p.m.

CONCURRENT SESSION 1:

RNAi Therapeutics: Hype or Hope?

Session Co-Chairpersons: Frank McCormick, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA and Judy Lieberman, Harvard Medical School, Boston, MA, USA

Opportunities for systemic treatment using siRNA in nanoparticles

Frank McCormick

Targeting TNBC and epithelial tumor-initiating cells with aptamer-siRNA chimeras

Judy Lieberman

Prospects for miRNA and lncRNA-based cancer therapeutics

Reuven Asami, Netherlands Cancer Institute, Amsterdam, The Netherlands

Additional speaker to be announced

(*subject to change, visit www.AACR.org/TargetsConference for an updated program schedule)

CONCURRENT SESSION 2:

Molecular Diagnostics: Bringing the Latest Technologies to Clinical Development

Session Co-Chairpersons: Anthony John Iafrate, Massachusetts General Hospital, Boston, MA, USA and Jean-Charles Soria, Institute Gustave-Roussy, Villejuif, France

Concordance and divergence in driver mutations between primary and metastasis: Focus in NSCLC and colon cancer

Jean-Charles Soria

Additional speakers to be announced

CONCURRENT SESSION 3:

Novel Laboratory Models to Assess Cancer Therapeutics (GEMS, PDX, Primary Cell Cultures/Feeder Cell System)

Session Co-Chairpersons: William R. Sellers, Novartis Institutes for BioMedical Research, Cambridge, MA, USA, and Norman E. Sharpless, Lineberger Comprehensive Cancer Center, UNC School of Medicine, Chapel Hill, NC, USA

Title to be announced

Norman E. Sharpless

Conditionally reprogrammed cells for personalized medicine

Richard Schlegel, Georgetown University School of Medicine, Washington, DC, USA

Title to be announced

William R. Sellers

Additional speaker to be announced

CONCURRENT SESSION 4:

Targeting Apoptotic Regulators (MDM2, BCL-2 Inhibitors)

Session Co-Chairpersons and speakers to be announced

Proffered Paper Session 2

5:30 p.m.-6:30 p.m.

Poster Session B / Exhibit Show (Continued)

6:30 p.m.-7:30 p.m.

TUESDAY, OCTOBER 22

Breakfast

7:00 a.m.-8:00 a.m.

PLENARY SESSION 5:

Genomic Heterogeneity in Cancers: Implications for Responsiveness

8:00 a.m.-10:00 a.m.

Session Co-Chairpersons: Elaine R. Mardis, Washington University School of Medicine, Saint Louis, MO, USA and Kornelia Polyak, Dana-Farber Cancer Institute, Boston, MA, USA

Heterogeneity in DCIS and invasive breast cancers

Kornelia Polyak

Mathematical modeling of tumor heterogeneity

Franziska Michor, Dana-Farber Cancer Institute, Boston, MA, USA

An evolutionary view of heterogeneity in glioblastoma

Simon Tavaré, Cancer Research UK Cambridge Institute, Cambridge, United Kingdom

Title to be announced

Elaine R. Mardis

Break

10:00 a.m.-10:30 a.m.

PLENARY SESSION 6:

CTCs, Noninvasive Monitoring of Cancers

10:30 a.m.-12:30 p.m.

Session Co-Chairpersons: Alberto Bardelli, IRCC - University of Turin Medical School, Candiolo, Italy and Daniel A. Haber, Massachusetts General Hospital, Charlestown, MA, USA

Liquid biopsies to monitor response and resistance to targeted therapies

Alberto Bardelli

Cancer exomes in plasma to track clonal evolution and resistance

Carlos M. Caldas, Cancer Research UK Cambridge Research Institute, Cambridge, United Kingdom

Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing

Mark Sausen, Personal Genome Diagnostics, Baltimore, MD, USA

Title to be announced

Daniel A. Haber

(*subject to change, visit www.AACR.org/TargetsConference for an updated program schedule)

Scientific Program and Schedule at-a-Glance*

Poster Session C / Exhibit Show

12:30 p.m.-3:00 p.m.

CONCURRENT SESSIONS 5-8

3:15 p.m.-5:15 p.m.

CONCURRENT SESSION 5:

Back to the Future: Targeting Cell Cycle and DNA Repair

Session Co-Chairpersons: Alan D. D'Andrea, Dana-Farber Cancer Institute, Boston, MA, USA and Yves G. Pommier, National Cancer Institute-CCR, Bethesda, MD, USA

PARP inhibitors: Trapping of PARP and rational for combinations
Yves Pommier

Targeting the Fanconi anemia/BRCA pathway

Alan D. D'Andrea

Additional speakers to be announced

CONCURRENT SESSION 6:

EMT, Cellular Plasticity, Cellular Differentiation, and Response to Therapies

Session Co-Chairpersons: Jeffrey E. Settleman, Genentech, Inc., South San Francisco, CA, USA and Robert A. Weinberg, MIT Whitehead Institute for Biomedical Research, Cambridge, MA, USA

Cancer stem cells and the EMT

Robert A. Weinberg

Breast cancer stem cells

Jenny Chang, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX, USA

Cell plasticity promotes drug resistance and pathway redundancy

John D. Haley, OSI Pharmaceuticals, Farmingdale, NY, USA

Reversible tolerance to anticancer drugs

Jeffrey E. Settleman

CONCURRENT SESSION 7:

Developing Combination Therapy Approaches in the Lab and Clinic

Session Co-Chairpersons: Jeffrey A. Engelman, Massachusetts General Hospital, Charlestown, MA, USA and Jose Baselga, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Speakers to be announced

CONCURRENT SESSION 8:

Using Genomics from Cell Line Screens to Inform Drug Development

Session Co-Chairpersons: Mathew Garnett, Wellcome Trust Sanger Institute, Hinxton, Cambridge, United Kingdom and Levi A. Garraway, Dana-Farber Cancer Institute, Boston, MA, USA

Speakers to be announced

Proffered Paper Session 3

5:30 p.m.-6:30 p.m.

Poster Session C / Exhibit Show (Continued)

6:30 p.m.-7:30 p.m.

WEDNESDAY, OCTOBER 23

Breakfast

7:00 a.m.-8:00 a.m.

PLENARY SESSION 7: Immunotherapy

8:00 a.m.-10:00 a.m.

Session Co-Chairpersons: Alexander M. M. Eggermont, Institut Gustave-Roussy, Paris, France and Carl H. June, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA

Speakers to be announced

Break

10:00 a.m.-10:30 a.m.

PLENARY SESSION 8:

Regulatory Science and Policy Session

10:30 a.m.-12:30 p.m.

Session Co-Chairpersons and speakers to be announced

Closing Remarks / Adjourn

12:30 p.m.-12:45 p.m.

(*subject to change, visit www.AACR.org/TargetsConference for an updated program schedule)

Abstract Submission Categories and Guidelines

When submitting an abstract for the **2013 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference** using the Online Abstract Submission System, authors will be asked to choose the appropriate category below that best describes the scientific content of the abstract. This information will be used as a guide by the members of the Scientific Committee in their review of abstracts. Before making a selection, authors should review the entire list for the most appropriate abstract category.

Angiogenesis and antiangiogenesis agents	MAPK pathways
Animal models	Metabolism
Apoptosis, necrosis, and autophagy	Metastasis and invasion
Bioinformatics	Molecular classification of tumors
Biomarkers	Monoclonal antibodies
Cancer stem cells	mTOR / PI3-Kinase
Cell cycle regulators	Natural products
Cellular responses to therapy	New molecular targets
Chemistry	Novel assay technology
Chemoprevention	Pediatric early drug development
Clinical trials	Pharmacogenetics, pharmacogenomics, and therapeutic response
Differentiation	Pharmacokinetics and pharmacodynamics
DNA repair and modulation	Protein-protein interaction
Drug delivery	Radiotherapeutics
Drug design	RNA and RNA-based technologies and therapies
Drug metabolism, transport, and biodistribution	Signal transduction modulators
Drug resistance and modifiers	Target identification and validation
Drug screening	Therapeutic agents: Biological
EGFR / Her2	Therapeutic agents: Small molecule kinase inhibitors
Epigenetic targets	Therapeutic agents: Other
Gene therapies	Topoisomerase inhibitors
Genomics, proteomics, and target discovery	Toxicology
Heat shock proteins	Tubulin-interacting agents
Hormonal agents and therapy	Tumor immunology targets
Imaging	Tumor microenvironment
In vitro and in vivo models for targets	Tumor suppressors

Abstract Submission Categories and Guidelines

AACR Online Abstract Submission System

Authors must submit abstracts for presentation at the 2013 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference using the AACR Online Abstract Submission System, which will be available at www.aacr.org/targetsconference in mid-June. You can create, modify, and submit abstracts until the Monday, August 12 deadline. Complete instructions on the use of the AACR Online Abstract Submission System will be provided on the website.

Abstract Control Number

An Abstract Control Number will be assigned to each abstract submitted online and will be listed on all e-mail correspondence regarding the abstract. Please refer to the Abstract Control Number in any abstract communications.

Length of Abstracts

The combined length of the abstract body, title, and tables may not exceed 2,600 characters, not including spaces and the author list. Tables count for 800 characters against the limit; submission of figures is not permitted. Submission cannot be completed for abstracts that exceed the character limit.

Copyright Transfer/Permission to Record/Abstract Presentation

On behalf of all authors, the corresponding author must agree to:

1. Transfer copyright of the abstract to the AACR for publication;
2. Grant the AACR permission to record the audio portion (if any) of the abstract presentation and to collect all revenue from subsequent sales; and
3. Confirm that an author will attend the 2013 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference to present the abstract.

Abstract Submission Deadline

The deadline for abstract submissions is 11:59 p.m. U.S. Eastern time, Monday, August 12, 2013. Abstracts submitted in any form after the deadline will not be considered by the Scientific Committee. Note: Submitting an abstract for presentation at the 2013 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference does not constitute registration for the conference. Abstract presenters must register to attend the conference; information is available online at www.aacr.org/targetsconference.

The AACR will not be responsible for the acceptance and processing of revised abstracts that are not submitted in compliance with the posted regulations. No changes may be made to abstracts after the August 12 deadline.

Disclosure of Chemical Structures

At the time of abstract submission, the submitting author is required to state whether chemical compounds were used in the scientific work to generate the data in the proffered paper. Chemical compounds are defined as low-molecular-weight (generally <1000 g/mol) organic or inorganic molecules, peptides, or proteins/nucleic acids co-crystallized with low-molecular-weight molecules. If chemical compounds were used, the corresponding author is further required to indicate whether the complete chemical structures of the compounds used will be disclosed at the time of presentation at the conference. The chemical structures are not required to be included at the time of abstract submission; rather, an indication of the intent to disclose any such structures at the time of presentation is required.

The Scientific Committee will then evaluate the information provided by the corresponding author and determine the acceptability of the proffered paper for presentation. Those who do not intend to disclose chemical structures may have their abstracts rejected for participation; however, a limited number of these abstracts may be accepted for presentation if deemed to be of sufficient scientific merit.

Content of Abstracts

Authors who submit abstracts confirm that they have not previously published these data, that they have not previously presented them at another large national annual scientific meeting, and that they are not planning to present or publish them prior to the dates of the 2013 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference. Each abstract should contain: (a) an introductory sentence indicating the purposes of the study; (b) a brief description of pertinent experimental procedures; (c) a summary of the new, unpublished data; and (d) a statement of the conclusions. Authors must accept sole responsibility for the statements in their abstracts. Abstracts should be carefully proofread to avoid errors in the published literature. American spelling should be used throughout; for more information regarding American spelling, please refer to *Scientific Style and Format: The CSE Manual for Authors, Editors, and Publishers*, Seventh Edition (Council of Science Editors, 2006).

Accommodations and Travel

The conference will be held at the John B. Hynes Veterans Memorial Convention Center, located in the heart of Boston's historic Back Bay neighborhood and just 5 miles / 8 km from Boston's Logan International Airport.

The AACR has contracted with several hotels to offer reduced room rates for attendees at this year's conference. Based on the feedback from the 2009 conference held in Boston, AACR has expanded the number of hotels to offer a wider variety of options for attendees.

The Sheraton Boston Hotel will serve as the headquarters hotel for the 2013 Molecular Targets and Cancer Therapeutics conference, with the Hilton Boston Back Bay, Boston Park Plaza Hotel & Towers, Colonnade Hotel, and Midtown Hotel also serving as official conference hotels. Please review the pricing options below and the map on the inside back cover before making any reservations. The Boston Park Plaza is the only hotel that provides a shuttle service (limited schedule) to the Hynes Convention Center.

Hotel reservations can be made by phone, mail, fax, or online through AACR Housing. AACR Housing will open Tuesday, June 11 and accept reservations through Monday, September 16. After September 16, reservations and rates will be subject to hotel availability. Room reservations must be guaranteed with a major credit card.

To make a reservation please complete the official housing form on page 14 or visit the Accommodations and Travel webpage www.aacr.org/targetsconference.

Travel to Boston

The closest major airport to the Convention Center and conference hotels is Boston's Logan International Airport (BOS), located approximately 5 miles / 8 km (15-20 minutes) from the Hynes Convention Center.

The AACR has named Gant Travel Management as its official travel coordinator for this conference. Gant will provide custom itineraries with the lowest applicable airfares and best journey time. Fly on United Airlines, the official airline of this conference, and save with special discounts exclusive to attendees and guests. Full mileage credit will be earned by frequent flyer club members. To receive the exclusive discounts, please contact Gant toll-free at (877) 924-2298 [(630) 227-3818 if outside of the U.S./Canada] or by e-mail at aaacr@ganttravel.com.

Gant is open from 7:30 a.m. to 6:00 p.m. U.S. Central time, Monday through Friday.

Amtrak train service is also readily available for attendees traveling from the Eastern U.S. to Boston. Amtrak's Back Bay Station is approximately 1 mile from the Hynes Convention Center.

International Travel

Researchers from more than 50 different countries around the world regularly participate in this joint AACR-NCI-EORTC conference. If you plan to attend the 2013 Molecular Targets and Cancer Therapeutics conference, please contact the American Consulate in your country to review the current regulations for travel to the United States. Obtaining the proper documentation may take several weeks or months, depending on your location, so please contact the consulate as soon as possible if you are considering attending this conference. Information is also available on the U.S. Department of State website at <http://www.travel.state.gov/>.

For additional information on travel to Boston and ground transportation once you arrive, please visit www.aacr.org/targetsconference and follow the link for Accommodations and Travel.

Map Number	HOTELS	Single/Double Rate	Triple/Quad Rate	Smoke-Free Hotel	Distance from Convention Center	Business Center	Coffee Maker	High-Speed Internet	Onsite Fitness Center	Indoor/Outdoor Pool	Restaurants	Bars	Room Service	Comp. Breakfast	Self Parking	Valet Parking
Headquarters																
1	The Sheraton Boston 39 Dalton Street	\$249/\$249	\$269/\$289	Y	0.25 miles	Y	Y	\$9.95	No charge	Indoor	1	1	24 hours	N	\$43	\$46
Convention Center																
2	Hilton Boston Back Bay 40 Dalton Street	\$245/\$245	\$265/\$285	Y	0.25 miles	Y	Y	No charge	No charge	Outdoor	1	1	6:00 a.m.-12:00 a.m.	N	\$41	N
3	The Colonnade Hotel Boston 120 Huntington Avenue	\$254/\$254	\$284/\$314	Y	0.5 miles	Y	Y	No charge	No charge	Outdoor	1	1	6:00 a.m.-12:00 a.m.	N	\$42	N
4	Midtown Hotel 220 Huntington Avenue	\$169/\$169	\$179/\$189	Y	0.5 miles	Y	Y	No charge	N/A	Outdoor	0	0	N	N	\$22	N
5	The Boston Park Plaza Hotel and Towers 50 Park Plaza at Arlington St.	\$224/\$224	\$244/\$264	Y	1.0 miles	Y	Y	\$12.50	No charge	N/A	1	1	6a.m.-2p.m. 3p.m.-11p.m.	N	N	\$46

Room rates are in U.S. Dollars.

For more information on the convention center and conference hotels, please visit www.aacr.org/targetsconference and follow the link for Accommodations and Travel. Please note: This information was accurate as of May 2013. Fees and amenities listed are subject to change without notice.

Continuing Medical Education

Continuing Medical Education Activity *AMA PRA Category 1 Credits™* will be available. Details will be available online at www.aacr.org/targetsconference.

Financial Support for Attendance

AACR Scholar-in-Training Awards

AACR members in good standing who are graduate and medical students, postdoctoral fellows, or physicians-in-training and submit abstracts may be considered for a Scholar-in-Training Award to offset a portion of the registration, travel, and subsistence expenses incurred in attending this conference. The number of awards provided and the dollar amounts of each award will be based on available funding. The award application deadline is Monday, August 12. Additional information and application instructions are available online at www.aacr.org/targetsconference.

AACR Minority-Serving Institution Faculty Scholar Awards in Cancer Research

The AACR offers awards in cancer research for participation in its meetings and conferences to full-time faculty of minority-serving institutions, i.e., historically black colleges and universities (HBCUs), Hispanic-serving institutions (HSIs), Indian tribally controlled colleges and universities (ITCCUs), and other postsecondary institutions as defined by the U.S. Department of Education, who are scientists at the Assistant Professor level or above and have completed postdoctoral studies or clinical fellowships and hold full-time faculty status. All candidates must have a degree (e.g., M.D., Ph.D., D.V.M., D.Sc.) in a field relevant to cancer research. The AACR MSI Faculty Scholar Awards program is supported by a generous grant from the Center to Reduce Cancer Health Disparities of the National Cancer Institute. The purposes of the awards are to increase the scientific knowledge base of faculty members at MSIs, to encourage them in their research, and to assist in inspiring their students to pursue careers in cancer research. The award application deadline is Monday, August 12. Additional information and application instructions are available online at www.aacr.org/targetsconference.

AACR Minority Scholar Awards in Cancer Research

The AACR is pleased to administer this important award program that is supported by a generous grant from the Center to Reduce Cancer Health Disparities of the National Cancer Institute and provides funds for the participation of meritorious minority scientists in AACR meetings and conferences. These awards are

intended to enhance the education and training of minority researchers and to increase the visibility and recognition of minorities involved in cancer research. Eligible scientists are full-time predoctoral (graduate or medical) students or residents, clinical or postdoctoral fellows, or junior faculty who are either engaged in cancer research or who have the training and potential to make contributions to this field. This program applies only to racial/ethnic minority groups that have been identified by the NCI as being traditionally underrepresented in cancer and biomedical research. These groups are African American/Black, Alaskan Native, Hispanic American, Native American, and Native Pacific Islander. Only citizens of the United States or Canada or scientists who are permanent residents of these countries may receive one of these awards. The award application deadline is Monday, August 12. Additional information and application instructions are available online at www.aacr.org/targetsconference.

Registration

Individuals wishing to attend the conference can register online beginning in early June at www.aacr.org/targetsconference or by returning the registration form on page 15 of this brochure. Attendee registration includes admission to all scientific sessions, poster sessions, the networking reception on October 19, conference continental breakfasts on October 20, 21, 22, and 23, refreshment breaks, and refreshments during the evening poster sessions on October 20, 21, and 22. All registrants agree to follow the Policies and Procedures for the conference outlined on page 12 of this brochure.

Registration will not be processed without full payment. Government or other payment orders are not accepted. All payments must be in U.S. currency, drawn on a U.S. bank. Visa, MasterCard, and American Express are also accepted for payment. Places at the conference are on a first-come, first-served basis, according to the date of registration.



Registration Rates

Please note the two (2) options for registering below. PREMIUM (which includes access to webcasted sessions) and STANDARD (which does not include access to webcasted sessions).

Premium Package (Includes full individual access to the *2013 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics* webcast)

	Early Until August 9	Advance August 10-September 20	Regular / Onsite After September 20
AACR/EORTC Members			
Active/Affiliate (Nonprofit)	\$ 754	\$ 894	\$ 924
Active/Affiliate (Industry)	\$ 894	\$1,054	\$1,194
Associate	\$ 524	\$ 624	\$ 654
Patient Advocate ²	\$ 274	\$ 299	\$ 324
Non Members			
Nonprofit	\$ 964	\$1,124	\$1,174
Industry	\$1,194	\$1,494	\$1,594
Pre/Postdoctoral Student ¹	\$ 644	\$ 744	\$ 774
Patient Advocate ²	\$ 374	\$ 399	\$ 424

Standard Package (Does not include webcast access)

	Early Until August 9	Advance August 10-September 20	Regular / Onsite After September 20
AACR/EORTC Members			
Active/Affiliate (Nonprofit)	\$ 655	\$ 795	\$ 825
Active/Affiliate (Industry)	\$ 795	\$ 955	\$1,095
Associate	\$ 425	\$ 525	\$ 555
Patient Advocate ²	\$ 175	\$ 200	\$ 225
Non Members			
Nonprofit	\$ 815	\$ 975	\$1,025
Industry	\$ 995	\$1,295	\$1,395
Pre/Postdoctoral Student ¹	\$ 495	\$ 595	\$ 625
Patient Advocate ²	\$ 225	\$ 250	\$ 275
Guest/Spouse	\$ 175	\$ 175	\$ 175

¹ - Students registering onsite must show a valid student ID. Nonmember pre-/postdoctoral students must have their registrar, dean, or department head certify that they are enrolled at the university and working toward a degree or fellowship in a field related to cancer research.

² - Patient advocates registering for this conference must send a personal biography and pamphlet of their organization to the AACR Survivor and Patient Advocacy Department at advocacy@aacr.org for verification.

Spouse/Guest fee includes only meals and social activities listed on page 9. It does NOT admit individuals to lecture sessions. Conference registrants (scientific and spouse/guest) will receive one complimentary drink ticket to the Networking Reception. Space permitting, onsite registration will be available at the Hynes Convention Center beginning on Saturday, October 19. All registrations are for the full conference.

Refund Policy

All cancellations must be made in writing by September 20, 2013. Cancellations can be e-mailed, faxed, or mailed to the following:

AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics
P.O. Box 6271, Broadview, IL 60155.
Fax: (708) 344-4444
E-mail: molecular@compusystem.com

Survivor and Patient Advocate Opportunities

The AACR strongly encourages the involvement of survivors and patient advocates in this conference and is pleased to offer discounted registration rates to this group. Advocates who are members of the AACR will receive a registration discount. Advocates must submit a biography or a curriculum vitae and the advocate verification form to receive the discounted rate. You can find the advocate verification form online at www.aacr.org/survivorsandadvocates. For advance registration, please contact Karen Russell Mills at advocacy@aacr.org or (215) 446-7104. Onsite registration at this special rate will not be available.

AACR Membership

AACR membership is available to individuals who are interested in joining the AACR and registering for this conference at discounted member rates. AACR membership offers an array of benefits, some of which include: reduced subscription rates to AACR's eight scientific journals; abstract sponsorship privileges for AACR Annual Meetings; and networking and scientific exchange with leading researchers. The AACR is also eager to support the exchange of knowledge and research with investigators who are located in countries with emerging economies. Significantly reduced membership dues are available for these investigators.

Individuals interested in joining AACR and registering at the early registration rate must submit an application no later than August 2, 2013. Those individuals interested in registering at the advance registration rate must submit applications no later than September 13, 2013. Only individuals who are listed on the

membership rolls as of October 14, 2013, will be accorded the privilege of registering for the conference at the member rates noted on page 10. If, upon review of the membership application, a candidate is deemed ineligible for the membership category to which he or she has applied then the candidate will need to register at the nonmember rate. Membership information and the Membership Application form can be downloaded from the AACR website at www.aacr.org. Please contact the AACR Membership Department at (215) 440-9300 or membership@aacr.org with any questions.

Assistance for Attendees with Disabilities

This AACR-NCI-EORTC conference is accessible to all registrants. Attendees with special requirements for transportation, hotel accommodations, or other facilities associated with the conference should notify the AACR in advance when registering or by e-mailing meetings@aacr.org.

Location

The conference will be held at the John B. Hynes Veterans Memorial Convention Center (the Hynes Convention Center), located in Boston's Back Bay area. The Center is conveniently located close to public transportation for easy access by Boston's "T" subway system and commuter rails. In many ways, the Hynes Convention Center is a city within a city. The Hynes is connected to not one, but two major retail complexes, Prudential Center and Copley Place, that contain just about everything attendees need during the conference. Fast food, fine dining, sundries, personal services, and world-class shopping - all under one roof. Attendees can experience a serious slice of Boston without ever worrying about the weather! Enter the Prudential Center through the Hynes South Lobby. Turn right for the Sheraton Boston Hotel and its meeting rooms, Starbucks, dining, and business center. A left turn leads to the Prudential Center, home to an extensive food court and fine dining, boutiques, and shops including Saks Fifth Avenue and Lord & Taylor.

Boston attractions provide more compelling things to see and do than any other convention city in North America. From America's history found along the Freedom Trail to world-famous museums and international cuisine. The Theater District, located only minutes from the Hynes Center, hosts Broadway plays and musicals. Jazz clubs, dance clubs, comedy clubs, and improv theaters add to the entertainment scene. And for those who consider shopping to be the ultimate entertainment, Boston offers the boutiques of Newbury Street and the shops at Quincy Market.

Policies and Procedures

- Children under 12 years of age are not permitted in any scientific session, poster session, or the Exhibit Hall at any time. Children cannot be left unattended or unsupervised in the Convention Center.
- Cell phones and other electronic devices must be turned off or placed on “silent” mode before entering a session.
- Attendees may contact the AACR Office in Room 207 of the Hynes Convention Center for any lost items.
- Poster presenters are solely responsible for placing their poster on the assigned poster board and removing their poster according to the schedule provided. AACR cannot be responsible for any posters that are not removed at the designated time. Posters left in the Exhibit/Poster Hall after that time may be discarded.
- Poster presenters should not leave any items at their poster board unattended, including poster tubes, meeting bags, Programs, personal items, etc. AACR is not responsible for any items left in the Exhibit/Poster Hall.
- Smoking is prohibited in all areas of Hynes Convention Center and at sessions and social events held in other venues.
- Use of photographic or other recording or transmission devices is strictly prohibited in all scientific and poster sessions without the express permission of the presenter.
- A professional photographer and videographer may be on site to document conference events and activities between October 19 and 23, 2013. Photographs and video footage are the sole property of AACR. By registering for and attending these events, attendees understand that AACR may use their likenesses for future promotional purposes. If you do not wish to be photographed, please notify the photographer and/or videographer on site.
- Attendees violating any of the Policies and Procedures may be escorted from or asked to leave the Conference.

Oral Presentations of Highly Rated Abstracts

Oral presentations of highly rated abstracts will be featured in one-hour sessions on Sunday, Monday, and Tuesday, from 5:30 p.m.-6:30 p.m. All abstracts submitted by the August 12 deadline will be considered. Anyone selected to present an oral presentation will be notified approximately three weeks after the abstract submission deadline.

Social Media

The use of social media is encouraged in and around the 2013 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference, but please adhere to the AACR's social media guidelines and accepted social media etiquette. Please be aware of the following guidelines:

DO

- Follow us on Twitter—@AACR, @EORTC, and @theNCI—and use the hashtag #Targets13 during the conference.
- Follow us on Facebook.
- Blog about the conference and what you are hearing and seeing (but without sharing details of any data presented: follow journal rules about data sharing).
- Converse with other attendees.
- Provide feedback to AACR staff and the program committee – discuss topics of interest and/or speakers for future conferences.
- Communicate with respect, being mindful of diversity and tolerant of differences you may encounter. Keep criticism constructive, and listen carefully to others to understand their perspectives.

DON'T

- Use photographic or other recording devices—this is strictly prohibited in all plenary and poster sessions.
- Capture, transmit or re-distribute data presented at the conference—this may preclude subsequent publication of the data in a scholarly journal. Please do not jeopardize your colleagues' work!
- Engage in rudeness or personal attacks.

Press

Members of the national and international media depend on the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference to provide the most up-to-date information on drug development in oncology. At this year's conference, the American Association for Cancer Research Office of Communications and Public Relations will be staffing a full-service press room for working journalists with conference materials and office equipment. Reporters who are interested in registering for the conference should contact Lauren Riley at lauren.riley@aacr.org. The AACR does not release media lists, but we will distribute company-sponsored press releases in the press room under certain guidelines. Public relations officers who wish to distribute press releases related to the conference should contact Jeremy Moore at (215) 446-7109 or jeremy.moore@aacr.org for more information.

Support Opportunities

Support and generous recognition opportunities – ranging from \$5,000 to \$100,000 – are available for this conference. Benefits include complimentary registrations, networking opportunities, and more. The AACR welcomes support from corporations, foundations, and other organizations that are interested in helping to defray a portion of the cost of presenting this important international conference. For further information regarding these support opportunities, please contact Iain Mitchell in the AACR Development Department at (215) 446-7120, or iain.mitchell@aacr.org.

Exhibit Information

Opportunities are available to reserve an exhibit space at this conference. Over 3,000 scientists and researchers who are leading the discovery and drug development effort against cancer worldwide are expected to attend this year's conference. Don't miss this opportunity to further your business by meeting new contacts from industry, government, and academia. For further information please contact Lisa A. McGlashen, AACR Exhibits Manager at (215) 446-7183 or exhibits@aacr.org.

Webcasts of Sessions

As in previous years, the AACR will make a limited number of selected sessions available free to all interested researchers. In addition, attendees can now purchase exclusive online streaming access to the audio and slides of all scientific sessions presented at the 2013 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference.*

- Presentation slides synchronized with recorded audio presentations
- Speakers' mouse movements captured and included in playback
- Available on PC, Mac, and Android devices with Adobe Flash Player 10.1
- Presentations searchable by session title, presentation title, and speaker name
- Exclusive access to online content for 15 months after the conference

Purchase access to the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics by selecting the Premium Package when registering and get the lowest rates.

**Participation in the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics webcasts is left to the discretion of each speaker. As a result, some presentations may not be available for webcast, and some webcast presentations may not include all slides. Access is granted via individual username and password.*



Official Housing Instructions and Form (please print or type)

Housing Instructions

Reservations can be made by phone, mail, fax, or online through AACR Housing. AACR Housing will open at 9:00 a.m. U.S. Eastern time on Tuesday, June 11, and accept reservations through Monday, September 16. After September 16, reservations and rates will be subject to hotel availability. Room reservations must be guaranteed with a major credit card.

Online

In order to reserve a room online, you must supply a credit card. AACR Housing will provide descriptions, amenity information, and photographs for each AACR official hotel. Additionally, a map showing the location of all hotels and the Hynes Convention Center will be available. AACR Housing will also provide up-to-the-minute availability and provide immediate confirmation of your hotel reservation.

Phone

AACR Housing agents will be available to accept reservations as well as provide information on the AACR official hotels Monday through Friday from 9:00 a.m. to 9:00 p.m. U.S. Eastern time. You will be required to supply a credit card if reserving your hotel room by phone. Once your reservation is complete you will receive immediate confirmation either by e-mail or fax. **AACR Housing agents can be reached toll free at (866) 226-0305 [(415) 268-2096 for International callers].** When calling, please have the following information ready:

- Arrival and departure dates
- Hotel preferences
- Credit card number
- Any special requests
- Your address, phone number, fax number, and e-mail address

Fax

Complete the Official Housing Form found below and fax it to AACR Housing at (415) 216-2551. When faxing the form please be certain to indicate three choices. Please allow 24 hours for confirmation of your reservation. Your confirmation will be sent by e-mail. If no e-mail address is provided on the form, your confirmation will be faxed or mailed.

Mail

Complete the following Official Housing Form and mail it to the address below. Be certain to include either a credit card number or a check to guarantee your reservation. See the guarantee section for details. Please list the three hotels in order of preference. If the hotel you selected is unavailable, an AACR Housing Representative will contact you. Your confirmation will be sent by e-mail. If no e-mail address is provided on the form, your confirmation will be faxed or mailed.

**AACR Molecular Targets Housing
33 New Montgomery, Suite 1100
San Francisco, CA 94105**

For current availability, amenities, and additional information on conference hotels, please visit www.aacr.org/targetsconference and follow the link for Accommodations and Travel.

Hotel confirmations should be sent to

Last Name	
First Name	
Organization	
Address	
City/State (Country)	
Zip	
Telephone	Fax
E-mail	

Room Occupants

Last Name
First Name
Share with (List all occupants if applicable)

Hotel Preferences

Please rank all three hotels in order of preference, (1) being your first choice. If your first choice is unavailable, a reservation will be made at the next available hotel. Hotel requests will be honored on a first-come, first-served, space-available basis. Please see page 8 for hotel options.

1.	
2.	
3.	

Arrival, Departure, and Room Type

Arrival Date
Departure Date

Room Type: ☐ Single (1 bed/1 person) ☐ Double (1 bed/2 persons)
☐ Double/Double (2 beds/2 persons)
☐ Triple (2 beds/3 persons) ☐ Quad (2 beds/4 persons)
☐ Suite (If checked, an AACR Housing consultant will contact you.)

Bed type, smoking type, and special needs are on a request basis and cannot be guaranteed.

☐ Non-Smoking ☐ Smoking ☐ Other: _____



Special needs (specify): _____

Deposit and Cancellation Policies

Guarantee Information

All reservations must be guaranteed by a credit card or company check in the amount of one night's room and tax.

Checks must be received by September 16, 2013, and made payable to Convention Management Resources, Inc.

☐ Check enclosed (U.S. funds) Check #: _____
☐ VISA ☐ MasterCard ☐ American Express

Credit Card #	Expiration Date
---------------	-----------------

Print Name as it appears on card

Signature

Cancellation

Cancel your reservation at least 72 hours prior to your arrival date. Failure to do so will result in a forfeiture of your deposit or your credit card will be charged one night's room plus applicable hotel tax. Please contact AACR Housing to cancel your reservation.

Don't be a no-show!

If you fail to arrive at your reserved hotel on your confirmed arrival date, you will lose your room for all nights of your reservation and you will be charged a no-show fee of one night's room plus applicable hotel tax. Please contact AACR Housing if you wish to change your arrival/departure dates.

Register Online: www.AACR.org/TargetsConference**Name and Address Information**Check here if you are a member of: ☐ AACR Membership # _____ ☐ EORTC ☐ Nonmember☐ Dr.☐ Mr.☐ Ms.

Last/Family Name _____

First Name/Middle Initial _____

Title/Position _____

Department/Division _____

Institution _____

Street/Building or Post Office Box _____

City/State or Province _____

Zip or Postal Code/Country _____

Telephone _____

Fax _____

E-mail _____

Spouse/Guest's name, if registering _____

☐ New address. Please change my AACR mailing information.☐ If you will require special accommodations, please specify: _____**Nonmember Predoctoral Student/Postdoctoral or Clinical Fellow Certification**

"I certify that the above named person is presently enrolled at this University and working toward a degree or fellowship in a field related to cancer research."

Name (Registrar, Dean, or Dept. Head) _____

Signature (Registrar, Dean, or Dept. Head) _____

Title _____

University _____

Additional Registrant Information**Degree** Specify highest degree earned (indicate multiple doctoral degrees as appropriate, i.e., M.D., Ph.D.):☐ Ph.D. ☐ M.D. ☐ Pharm.D. ☐ D.V.M. ☐ Other (specify) _____**Scientific Research Focus** (check only one): ☐ Basic ☐ Translational ☐ Clinical ☐ Epidemiological ☐ Behavioral Science ☐ Other (specify) _____**Primary Area of Research** (check only one):☐ Behavioral Science☐ Biochemistry and Biophysics☐ Biostatistics☐ Carcinogenesis☐ Cellular Biology☐ Chemistry☐ Clinical Investigations☐ Computational Biology☐ Endocrinology☐ Epidemiology☐ Genetics & Genomics☐ Immunology☐ Molecular Biology☐ Preclinical Pharmacology & Experimental/Molecular Therapeutics☐ Prevention Research☐ Research Administration/Business Development☐ Virology☐ Other (specify) _____**Institution Type** (check only one):☐ Academic☐ Association☐ Cancer Center (NCI-designated)☐ Commercial☐ Foundation☐ Government☐ Hospital/Medical Center☐ Nonprofit Research Organization☐ Other _____☐ Other Cancer Center**Race or Ethnic Background** (check only one):☐ Caucasian ☐ African American or Black ☐ Hispanic or Latino ☐ Asian ☐ Native American ☐ Alaskan Native☐ Native Hawaiian or Pacific Islander ☐ Other _____**Gender:** ☐ Male ☐ Female

Information concerning gender and ethnic background is solicited to enable the association to ensure that its programs are appropriately serving all members of the cancer research community.

Registration Form (please print or type)Register Online: www.AACR.org/TargetsConference**Registration Categories**

Please circle the appropriate rate(s):

Premium Package (includes full individual access to the 2013 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics webcast)				Standard Package (does not include access to webcasts)			
Registration Rates in US\$	Early Until Aug. 9	Advance Aug. 10-Sept. 20	Regular/Onsite After Sept. 20	Registration Rates in US\$	Early Until Aug. 9	Advance Aug. 10-Sept. 20	Regular/Onsite After Sept. 20
AACR/EORTC Members				AACR/EORTC Members			
Active/Affiliate Nonprofit (MNP)	\$ 754	\$ 894	\$ 924	Active/Affiliate Nonprofit (MNP)	\$655	\$ 795	\$ 825
Active/Affiliate Industry (MIN)	\$ 894	\$1,054	\$1,194	Active/Affiliate Industry (MIN)	\$795	\$ 955	\$1,095
Associate (MAS)	\$ 524	\$ 624	\$ 654	Associate (MAS)	\$425	\$ 525	\$ 555
Patient Advocate ² (SUM)	\$ 274	\$ 299	\$ 324	Patient Advocate ² (SUM)	\$175	\$ 200	\$ 225
Nonmembers				Nonmembers			
Nonprofit (NNP)	\$ 964	\$1,124	\$1,174	Nonprofit (NNP)	\$815	\$ 975	\$1,025
Industry (NIN)	\$1,194	\$1,494	\$1,594	Industry (NIN)	\$995	\$1,295	\$1,395
Pre-/Postdoctoral Student ¹ (STU)	\$ 644	\$ 744	\$ 774	Pre-/Postdoctoral Student ¹ (STU)	\$495	\$ 595	\$ 625
Patient Advocate ² (SUN)	\$ 374	\$ 399	\$ 424	Patient Advocate ² (SUN)*	\$225	\$ 250	\$ 275
				Spouse/Guest (no admittance to lecture sessions)			
				\$175 \$ 175 \$ 175			
Total Enclosed or Charged US\$ _____				Total Enclosed or Charged US\$ _____			

Individuals interested in joining AACR and registering at the early registration rate must submit an application no later than **August 2, 2013**. Those individuals interested in registering at the advance registration rate must submit applications no later than **September 13, 2013**. Only individuals who are listed on the membership rolls as of **October 14, 2013**, will be accorded the privilege of registering for the conference at the member rates noted on the registration form. If, upon review of the membership application, a candidate is deemed ineligible for the membership category to which he or she has applied then the candidate will need to register at the nonmember rate. Membership information and the application form can be downloaded from the AACR website at www.aacr.org. Contact the AACR Membership Department at 215-440-9300 or membership@aacr.org with any questions.

Refund Policy: Requests for refunds must be made in writing. There will be a \$75 processing fee for cancellations until **September 20, 2013**. Beginning **September 21, 2013** no refunds can be given.

Financial Support for Attendance: AACR is pleased to provide financial assistance to eligible investigators for participation in this conference, subject to availability of funding. Additional information including award application instructions are available on the Financial Support for Attendance webpage for this conference.

Method of Payment

- ☐ Check or money order enclosed, payable to American Association for Cancer Research, drawn on a U.S. bank.
☐ VISA ☐ MasterCard ☐ American Express

Card # _____

Expiration Date _____

Print Name of Cardholder _____

Signature of Cardholder _____

Registration fees are payable in U.S. dollars only. Personal checks are acceptable if payable through a U.S. bank.

Return to:

2013 Molecular Targets
 CompuSystems, Inc.
 PO Box 6271
 Broadview, IL 60155
 Fax: (708) 344-4444

Courier Delivery:
AACR 2013 Molecular Targets
 2805 South 25th Avenue
 Broadview, IL 60155

¹ Nonmember pre-/postdoctoral students must have their registrar, dean, or department head certify that they are enrolled at the university and working toward a degree or fellowship in a field related to cancer research.

² If you are a nonmember Patient Advocate registering for this conference, you must send a biography and pamphlet of your organization to the AACR Survivor and Patient Advocacy Department at advocacy@aacr.org for verification.

AACR-NCI-EORTC International Conference
Conference Location

Meeting Location

★ John B. Hynes Veterans
Memorial Convention Center

Lodging

1. Sheraton Boston Hotel
(Headquarter Hotel)
2. Hilton Boston Back Bay
3. Colonnade Hotel
4. Midtown Hotel
5. Boston Park Plaza Hotel & Towers





615 Chestnut Street, 17th Floor
Philadelphia, PA 19106-4404
Telephone: 215-440-9300
Toll Free: 1-866-423-3965